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OBJECTIVE: High-resolution computed tomography (HRCT) allows the early detection of pathological changes
in the lung structure, and reproducible scoring systems can be used to quantify chest computed tomography
(CT) findings in patients with cystic fibrosis (CF). The aim of the study was to describe early HRCT findings
according to a validated scoring system in infants with CF diagnosed by newborn screening (NBS).
METHODS: This cross-sectional study included infants with CF diagnosed by NBS who were born between
January 2013 and January 2017 and who underwent HRCT scanning within the first year after diagnosis when
they were clinically stable. The CT scans were evaluated using the modified Bhalla score.
RESULTS: Thirty-two subjects underwent HRCT scanning. The mean total-modified Bhalla score was 3.6±2.1,
and 93.8% of the scans were abnormal. Pseudomonas aeruginosa airway colonization was associated with
increased modified Bhalla score values. Bronchial wall thickening was the most common feature (90.6%),
followed by bronchial collapse/consolidation (59.4%), mosaic attenuation/perfusion (50%), bronchiectasis
(37.5%) and mucus plugging (15.6%). Bronchial wall thickening was diffuse in most of the patients.
CONCLUSION: A substantial proportion of infants diagnosed with CF after detection by NBS already showed
evidence of lung disease. P. aeruginosa colonization was associated with increased Bhalla scores, highlighting
the importance of this CF pathogen in early structural lung disease. The presence of bronchial wall thickening at
such a young age may reflect the presence of airway inflammatory processes. The detection and quantification
of structural abnormalities with the modified Bhalla score may aid in the identification of lung disease before it
is clinically apparent.
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’ INTRODUCTION
Newborn screening (NBS) for cystic fibrosis (CF) has been
introduced in many parts of the world, including Brazil, with
the aim of obtaining a CF diagnosis as early as possible (1-3).
The prognosis for lung health has improved dramatically
with the implementation of NBS for CF. Since respiratory
disease has been well established as the major cause of mor-
bidity and mortality in children with CF (4), understanding the
factors responsible for the initiation and progression of lung
disease in early life is of utmost importance (5). Dysfunction in
the expression of CF transmembrane regulator (CFTR) leads
to a wide and variable array of presenting manifestations
and complications. As a general rule, mutations that are
considered severe are almost always associated with high
sweat chloride values and pancreatic insufficiency, but the
pulmonary phenotype is greatly influenced by other factors
(6). Patients initially develop transient Pseudomonas aerugi-
nosa infection that can be eradicated, but subsequent chronic
infection with P. aeruginosa or other pathogens, such as
those in the Burkholderia cepacia complex, is usually asso-
ciated with impaired lung function (7), poor nutritional
status and decreased survival in CF patients (8,9).
Although respiratory manifestations can be diagnosed
clinically by a medical history and physical examination along
with an assessment of growth parameters, these indicators are
relatively insensitive for lung disease evaluations (10). It is
well known that pulmonary function tests and chest X-rays
are relatively insensitive for indicators of lung disease, such as
early and localized lesions, especially in young children (11).
Several studies have found that chest computed tomography
(CT) images are more sensitive than chest X-rays in detecting
lung disease in CF patients (12-13).DOI: 10.6061/clinics/2019/e1399
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The development of high-resolution computed tomogra-
phy (HRCT) has allowed the early detection of pathological
changes in lung parenchyma as well as in the proximal and
distal airways (bronchial wall thickening, bronchiectasis,
mucoid impaction and lung hyperinflation) (11). Reproduci-
ble scoring systems can be used to quantify CT findings
(14,15). Furthermore, some studies that used HRCT scoring
systems for children and adults with CF and well-established
lung disease demonstrated more severe bronchiectasis in
the upper lobes (16-18). Although there have been studies
investigating the application of various CT scoring systems, a
formal recommendation for the routine use of such systems
has yet to be made for CF patients (19). In this scenario, the
modified Bhalla CT scoring system has been shown to be
reproducible and reliable for evaluating HRCT scans, even in
patients with mild CF lung disease (14).
The frequency and distribution of HRCT findings in infants
with CF lung disease detected by NBS is not yet fully under-
stood. Since the application of CF therapies is increasing in
young children, objective measures that allow the easy quan-
tification and represent the distribution of lung damage will
be useful not only for this purpose but also for initiating
prompt interventions when needed.
The aim of the study was to describe early HRCT findings
according to a validated scoring system in young children
with CF diagnosed by NBS.
’ MATERIALS AND METHODS
This cross-sectional study was a part of a cohort evaluation
conducted at the National Institute of Women, Children
and Adolescents Health Fernandes Figueira (IFF), which is
a technical-scientific unit of the Oswaldo Cruz Foundation
(FIOCRUZ) that is focused on education, research, service,
technological development and extension in the health of
women, children and adolescents. IFF/FIOCRUZ is the main
pediatric CF center located in the city of Rio de Janeiro, Brazil.
The study was approved by the Research Ethics Committee of
the National Institute of Women, Children and Adolescents
Health Fernandes Figueira (IFF/FIOCRUZ) (CAAE 58291616.
7.0000.5269).
All of the patients with CF-positive NBS tests in Rio de
Janeiro state are referred to this CF center to confirm or reject
the diagnosis. Once CF is confirmed, subjects are followed
until they are 18 years old by a multidisciplinary team. All
infants with CF diagnosed by NBS born between January
2013 and January 2017 were included in this study. The
medical records of those infants were reviewed.
At our CF center, the current follow-up strategy consists of
HRCT examinations beginning the first year after diagnosis
when the patients are clinically stable from a respiratory
standpoint; stability is defined as the absence of exacerbation
criteria (20,21). All HRCT scans were performed with a
16-MDCT scanner (Bright Speed Elitet, General Electric,
Milwaukee, WI, USA) with the following parameters: 100 kV,
60-80 mA, gantry rotation time 0.8 seconds per slice and
collimation 0.63 mm. This protocol routinely used in the
radiology department of the institution is in accordance with
the literature (13,22,23). All of the patients were scanned
without sedation and during spontaneous breathing. All CT
images were evaluated with lung window settings (level,
-700 HU; window, 1500 HU) and assessed by an experienced
pediatric radiologist who was blinded to the children’s cli-
nical data, clinical history and microbiology data. The HRCT
scoring system used in the present study was the modified
Bhalla CT score (24). Regarding the distribution, each scan
was divided into 6 lobes, with the lingula considered as a
separate lobe. The total score for each patient was obtained
by summing the scores for each morphological change,
which were attributed based on the severity/extent of the
abnormality. Scores from 0-3 were assigned to each of the
following categories: the severity of bronchiectasis, presence
of peribronchial thickening, extent of bronchiectasis, extent
of mucous plugging, presence of sacculations, degree of bro-
nchial involvement, number of bullae, presence of intralob-
ular septal thickening and presences of ground-glass infiltrate.
Scores from 0-2 were assigned for emphysema, collapse/
consolidation, mosaic attenuation/perfusion pattern, air trap-
ping and acinar nodule (24). The total score could range from
zero (absence of abnormalities) to 37 (all abnormalities present
and severe). The modified Bhalla score was previously
validated in CF patients in another study at this institution
(14) and was subsequently established not only for clinical
studies but also for patient follow-up (15,25).
For the descriptive analyses, mean values and their stan-
dard deviations (SDs) were presented for the continuous
variables. The categorical variables were described using
absolute and percentage frequencies. Student’s t-test and
analysis of variance (ANOVA) were used to compare the
variables with normal distributions. Nonparametric Mann-
Whitney and Kruskal-Wallis tests were used to compare
the numerical and categorical variables that had 2 or 3 cate-
gories, respectively. The normality assumption was verified
with the Shapiro-Wilk test. The analyses were conducted
using SPSS software (version 22) (26), and the significance
level was 5%.
’ RESULTS
Out of 200 patients who were followed in this CF center,
37 patients fulfilled the inclusion criteria (diagnoses obtained
from NBS), and 35 were included in the study (2 subjects
moved to another state).
The majority of patients were male (n=23; 65.7%), and
the mean age at diagnosis was 3.8 months. The z-score for
weight-for-length at the moment of CF diagnosis was -0.86
(SD±1.5). Regarding prenatal and newborn data, the mean
gestational age was 38.6 weeks (SD±1.1), and only one
patient presented a premature delivery (35 weeks). The mean
weight at birth was 3056.6 g (SD±456 g). The genotypes for
thirty-one patients were available, and F508del was present
in 61.2% of the included patients (32.2% homozygous/29%
heterozygous), while 38.7% presented other CFTR muta-
tions. Regarding colonization, 51.4% of the patients were free
of CF pathogens, while P. aeruginosa was present in 6 infants
(17.1%). Seven of the patients (20%) were completely asym-
ptomatic at the time of CF diagnosis. Respiratory signs (defi-
ned as tachypnea, abnormal auscultation, cyanosis or digital
clubbing) were found in 45.7% of the patients. Cyanosis and
digital clubbing were absent among all of the patients.
Twenty-three of the patients (65.7%) presented gastrointest-
inal signs/symptoms, including diarrhea, pallor or jaundice.
After the initial laboratory evaluation, which included the
fecal elastase level, pancreatic insufficiency was detected in
27 of the patients (77.1%) (Table 1).
Among the 35 patients, 32 (91.4%) underwent HRCT, and
3 died before the exam (2 from CF complications and 1 from
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an accident). HRCTwas conducted in patients at an average
of 8.9 months old.
The mean total modified Bhalla score was 3.6±2.1. Overall,
93.8% of the patients presented abnormal parameters. Only
two patients (6.3%) presented HRCT scans with normal para-
meters (scores of 0).
There were no statistically significant associations between
the mean modified Bhalla score and the age at the time of CT,
genotype, pancreatic sufficiency or overall symptoms. When
comparing the P. aeruginosa-colonized and noncolonized sub-
groups, the former presented an increased modified Bhalla
score, with a statistically significant difference (p-value 0.048)
(Table 2).
Regarding the frequencies of HRCT findings (Figure 1),
bronchial wall thickening was the most common parameter
(29 patients; 90.6%). Collapse/consolidation was identified
in 19 of the patients (59.4%) and was subsegmental in the
majority and segmental/lobar in only one patient. Mosaic
attenuation/perfusion pattern was detected in 16 of the
patients (50%). Bronchiectasis was identified in 12 of the
patients (37.5%), and all had mild severity (score of 1) and up
to five affected bronchopulmonary segments (score of 1).
Other parameters such as mucus plugging (5 patients; 15.6%)
and ground-glass infiltrate (3 patients; 9.4%), were less fre-
quent. Moreover, abnormalities such as sacculations/abscesses,
bullae, emphysema, acinar nodules and intralobular septal
thickening were absent in these patients.
A diffuse pattern, defined as impairment in 3 or more
lobes, was found for some parameters such as bronchial wall
thickening in 24/29 patients; mosaic attenuation/perfusion
pattern in 6/16 patients; collapse/consolidation in 4/19 and
bronchiectasis in 4/12 patients. Furthermore, an assessment
of the 29 patients with bronchial wall thickening revealed
that 7 patients presented only bronchial wall thickening
without any other abnormalities on HRCT. A total of 62%
(18/29) of patients also had collapse/consolidation, 51.7%
(15/29) of patients had a mosaic attenuation/perfusion
pattern, and 41.4% (12/29) of patients had bronchiectasis.
’ DISCUSSION
This study’s results provide outstanding insight into the
theory that the early development of CF lung disease, as
detected by HRCT, might begin in the first year of life. Most
infants (93.8%) presented abnormal CT scans, highlighting
the precocity of structural lung disease. In our study, bro-
nchial wall thickening was present in almost all of the
patients. This parameter has been frequently associated
with other findings that might be related to the impairment
of airway clearance (collapse/consolidation, mosaic atten-
uation/perfusion pattern) and inflammation, leading to
permanent structural lung disease (bronchiectasis). Further-
more, a diffuse pattern of bronchial wall thickening was found
in most patients. These findings at such an early age may
reflect already existing airway inflammatory processes that
randomly affect both lungs in stable infants with CF (28).
Table 1 - Anthropometric and clinical information of the
subjects (Rio de Janeiro. Brazil. 2013-2016).
Features Value
Sex (% male) 65.7% (23/35)
Birth weight (g)a 3056.6 (SD 452.5)
Gestational weeks at birth (weeks)a 38.5 (SD 1.2)
Age at CF diagnosis (months)a 3.8 (SD 1.9)
Weight-for-length (z-score)a,b -0.86 (SD 1.5)
Genotypec
F508del homozygous 32.2% (10/31)
F508del heterozygous 29% (9/31)
Other mutations 38.7% (12/31)
Colonizationd
No growthe 51.4% (18/35)
Pseudomonas aeruginosa 17.1% (6/35)
Other significant bacterial growthf 31.4% (11/35)
Symptoms
No symptoms 20% (7/35)
Respiratory symptoms 45.3% (16/35)
Gastrointestinal symptoms 65.7% (23/35)
Pancreatic insufficiencyg 77.1% (27/35)
Modified Bhalla score 3.6 (SD 2.1)
The results are expressed as the mean (SD) or % (n) unless otherwise
stated.
aMean.
bAccording to the World Health Organization Child Growth Standards
(27).
cComplete genotype data were not available for four children.
dBased on the presence of bacteria ever isolated before HRCT.
eNo bacterial growth consisted of isolation of only coliform and upper
respiratory tract flora.
fSignificant bacterial growth consisted of methicillin-susceptible
Staphylococcus aureus, methicillin-resistant Staphylococcus aureus,
Haemophilus influenzae, Stenotrophomonas maltophilia, and
Achromobacter xylosoxidans, but never P. aeruginosa.
gPancreatic insufficiency was considered according to a single assessment
of low fecal pancreatic elastase levels at diagnosis if available or by the
requirement for pancreatic enzyme replacement therapy at the time of
examination.
Table 2 - Correlation between subjects’ clinical/laboratory
features and modified Bhalla scores (Rio de Janeiro. Brazil. 2013-
2016).
Modified Bhalla score
(mean/SD or median/
min-max)
p-value
Age at HRCT
0-6 months 3.5 (1-7)
7-12 months 3 (2-7) 0.893b
412 months 3 (0-8)
Colonization
No growth 3 (0-7)a
Pseudomonas aeruginosa 6 (2-7)a 0.097b
Other significant bacterial growth 3 (2-8)
Genotype
F508del homozygous 4.20 (SD ±1.93)
F508del heterozygous 2.78 (SD ±1.64) 0.346c
Other mutations 3.58 (SD ±2.47)
Pancreatic insufficiency
Present 3.72 (SD ±2.11) 0.637d
Absent 3.29 (SD ±2.21)
Symptoms
Absent 3.5 (0-8) 0.837e
Present 3 (0-7)
Respiratory symptoms
Absent 4 (0-8) 0.782e
Present 3 (0-7)
Gastrointestinal symptoms
Absent 4.36 (SD ±2.62) 0.286d
Present 3.43 (SD ±1.80)
aThe p-value (Mann-Whitney test) of the comparison of no pathogens and
P. aeruginosa was 0.048.
bObtained by Kruskal-Wallis.
cObtained by ANOVA.
dObtained by Student’s t-test.
eObtained by Mann-Whitney test.
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Moreover, this research provides clear evidence of the
use of CT scans with no sedation, which prevents not only
sedation-associated morbidity but also possible bias in exam
findings, such as atelectasis in the posterior basal lung areas,
caused by general anesthesia. Therefore, our HRCT protocol
enables the use of CT as an important outcome measure-
ment tool for young infants whose lack of cooperation may
preclude other tests (12).
It is well known that CF scoring systems emphasize the
importance of some abnormalities and their pathological
factors; for example, mucus plugging plays a crucial role
in the pathogenesis of bronchiectasis, while bronchial wall
thickening reflects the presence of inflammation/infection
(11,21). Long et al. (29) demonstrated that the airways in
minimally symptomatic infants and young children (age
2.4±1.4 years) were thicker and more dilated than those in
normal control infants, and these findings increased with
age. Our study also found evidence of bronchial wall thick-
ening in most of the patients. This corroborates the results of
other studies that demonstrated that airway changes that
might lead to widespread structural lung disease associated
with CF begin early in life.
Our results also highlight the importance of P. aeruginosa in
early structural lung disease, as colonization with this CF
pathogen was associated with increased mean Bhalla scores
compared to no bacterial colonization. In contrast, Petrochei-
lou et al., who evaluating 45 CF children from 6-10 years old
whose diagnosis was made before 1 year of age, found that
P. aeruginosa might not be associated with abnormal CT
scans (9). These authors speculated that the absence of an
association between early P. aeruginosa infection and abnor-
mal subsequent chest CT findings may be attributed to agg-
ressive treatment. Other studies including adolescent or
older patients chronically colonized with methicillin-resistant
Staphylococcus aureus or P. aeruginosa identified increased
total modified Bhalla scores, reflecting the presence of
structural lung disease (14,15). Another study on the isola-
tion of proinflammatory pathogens (P. aeruginosa, Streptococ-
cus pneumoniae and Aspergillus species) in bronchoalveolar
lavage fluid showed a relationship between infection status
with these pathogens and CT findings in infants (29).
Furthermore, although quantitative assessments of HRCT
findings in CF patients allow accurate and reproducible
analyses, they may be cumbersome and time consuming.
Therefore, Oikonomou et al. evaluated five scoring systems
and selected parameters that had significant correlations
with pulmonary function test results. The severity of bro-
nchiectasis and bronchial wall thickening were found to
significantly worsen with time, and follow-up and might
be the leading causes of clinical deterioration (30). Another
study by our group that used a modified Bhalla score for
HRCT findings in 41 patients found that bronchiectasis,
bronchial wall thickening, and mucus plugging were present
in 70% of the analyzed images (14). In our study of young
children and infants, bronchiectasis, bronchial wall thicken-
ing, collapse/consolidation and mosaic attenuation/perfu-
sion were found in more than 50% of the patients. These
parameters might be considered early signs of structural
lung disease and might be used as future ‘‘simplified scores’’
for young patients. ‘‘Simplified scores’’, accounting for fre-
quent and early abnormalities, seem faster than complete
score calculations and could be easily adopted in clinical
practices.
Once NBS suggests an early diagnosis, the evaluation of
outcome measurements is a crucial step in maintaining high-
quality CF care for this young population (31).
Despite the fact that half of our subjects presented no
respiratory symptoms, more than 90% presented abnormal
HRCT findings, suggesting that structural lung disease
detectable on HRCT might precede the appearance of evident
clinical symptoms.
In this context, the use of imaging systems, especially CT
scoring systems, may help quantify structural lung abnorm-
alities and indicate the severity of lung disease (14,16,17,20).
A cross-sectional study by Mott et al. included 62 children
aged one to six years who were previously diagnosed with
CF by NBS and who underwent HRCT (18). Overall, 85% of
the scans were considered abnormal, with bronchiectasis
Figure 1 - High-resolution computed tomography findings. Bronchial wall thickening (1); Collapse/consolidation (2); Bronchiectasis (3);
Mucus plugging (4), Mosaic attenuation/perfusion pattern (5).
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detected in 61% of the subjects, mucus plugging in 47% of
the subjects and air trapping in 74% of the subjects. Our
study showed a higher prevalence of bronchial wall thick-
ening (more than 90%) and less frequent bronchiectasis than
those in Mott et al.’s study, probably due to the difference in
the subjects’ age ranges. These findings reinforce the idea
that structural lung disease worsens with age; thus, its early
detection might allow prompt interventions that prevent
increasingly severe structural damage.
The present study on tomographic scores in patients with
CF diagnosed by NBS is unprecedented in Brazil. All of the
patients with CF diagnosed by NBS who were referred to
this center were enrolled in this cohort and will be followed
until adulthood in the same unit. The present study limi-
tations include the cross-sectional design, as this population
was part of a cohort; however, we expect to address this issue
with a longitudinal prospective evaluation of disease evo-
lution. Furthermore, as we used a single scorer to assess all
the scans, there may be potential scoring bias. Nevertheless,
we think this is unlikely since this scoring system has been
previously validated with the same scorer in the same insti-
tution and was found to be a reproducible and reliable tool
(intraobserver correlation coefficient for total Bhalla score,
0.892; interobserver correlation coefficient, 0.814) (14). We
also propose a multicentric study to account for possible
regional differences among a large number of patients.
In both young children and patients with mild disease,
lung pathology is frequently underestimated. Thus, the early
detection of structural abnormalities and their assessment
with scoring systems may contribute to the identification of
minimally symptomatic lung disease and allow interventions
that can improve prognoses for NBS-diagnosed CF patients.
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